<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1356">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05143502</url>
  </required_header>
  <id_info>
    <org_study_id>Montelukast in nasal polyps</org_study_id>
    <nct_id>NCT05143502</nct_id>
  </id_info>
  <brief_title>Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.</brief_title>
  <official_title>Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the work is to examine the efficacy of montelukast as an adjunct to steroid&#xD;
      therapy in patients with chronic rhinosinusitis with nasal polyps.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population and Methods The study will be conducted at the otorhinolaryngology department in&#xD;
      Assiut University Hospital.&#xD;
&#xD;
        -  Study design: prospective randomized controlled trial.&#xD;
&#xD;
        -  .&#xD;
&#xD;
        -  Methodology:&#xD;
&#xD;
      After fulfilling all inclusion and exclusion criteria all patients will be subjected to&#xD;
&#xD;
      A. Full history taking including :&#xD;
&#xD;
        1. Personal History&#xD;
&#xD;
        2. History of sinonasal symptoms (nasal obstruction, nasal discharge, headache, hyposmia,&#xD;
           sneezing, itching, facial pain…etc)&#xD;
&#xD;
        3. History of nasal surgery.&#xD;
&#xD;
        4. Other ENT symptoms&#xD;
&#xD;
        5. General symptoms suggestive of atopy&#xD;
&#xD;
        6. History of general medical illness.&#xD;
&#xD;
      B. Examination :&#xD;
&#xD;
        -  1. General examination.&#xD;
&#xD;
        -  2. Full ENT examination.&#xD;
&#xD;
        -  3. Nasal endoscopy.&#xD;
&#xD;
      C. Investigations :&#xD;
&#xD;
      Multi-slice computer tomography (MSCT) of nose and paranasal sinuses axial, coronal and&#xD;
      sagittal cuts without contrast .&#xD;
&#xD;
      D. Management :&#xD;
&#xD;
      Patients will be divided into 2 equal groups. Patients in group A will be treated with&#xD;
      fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril&#xD;
      twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 monthes and oral&#xD;
      Prednisolone 40 mg/day for two weeks. Subjects in treatment group B will receive topical and&#xD;
      systemic steroids in an identical regimen only.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change at nasal polyp size</measure>
    <time_frame>after 12 weeks from the start of treatment</time_frame>
    <description>Each CRSwNP patient will undergo nasal endoscopy to score the polyp size (0-4) in both nasal cavities using a modified Lildholdt scoring system:&#xD;
0 = no nasal polyps.&#xD;
small nasal polyps not reaching the inferior border of the middle turbinate.&#xD;
nasal polyps reaching beyond the inferior border of the middle turbinate.&#xD;
large nasal polyps reaching the lower edge of the inferior turbinate&#xD;
very large nasal polyps in contact with the floor of the nasal cavity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal symptoms.</measure>
    <time_frame>after 12 weeks from the start of treatment</time_frame>
    <description>All participants will asked to score five sinonasal symptoms (nasal congestion/obstruction, anterior rhinorrhea, posterior rhinorrhea, loss of smell, and facial pain) from 0 to 4.&#xD;
0 = symptom-free/no symptom.&#xD;
mild symptom.&#xD;
moderate symptom.&#xD;
severe symptom.&#xD;
very severe symptom. This score will be assessed at the screening visit and follow-up visits at 4, 8 and 12 weeks. The total five-symptom score (T5SS) obtained with the sum of the individual symptoms (0-20).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological evaluation</measure>
    <time_frame>after 12 weeks from the start of treatment</time_frame>
    <description>CT scan of the nose and paranasal sinuses will performed to all patients before and after the treatment and staged using the Lund-Mackay (LMK) scoring system where each sinus (maxillar, anterior ethmoidal, posterior eth-moidal, frontal, esphenoidal) is scored for opacification (0, no opacity; 1, partial opacity; 2, total opacity), and the ostiomeatal complex is scored 0 (no obstruction) or 2 (obstruction). The uni-lateral score goes from 0 to 12 whereas the bilateral score goes from 0 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>after 12 weeks from the start of treatment</time_frame>
    <description>Subjects will complete validated questionnaire related to general quality of life lCSD (International Classification of Sinus Disease) before and after treatment. The ICSD records patients' symptoms of facial pain and pressure; headache ;nasal blockage Or congestion; nasal discharge; disturbance of smell; and Over all discomfort on a 0 to 10 ordinal scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Montelukast</condition>
  <condition>Chronic Rhinosinusitis With Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Montelukast Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group A (interventional group) will be treated with fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 monthes and oral Prednisolone 40 mg/day for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in treatment group B will receive topical and systemic steroids in an identical regimen only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Montelukast is a leukotrienes antagonist which has proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirin-exacerbated respiratory disease (AERD), all diseases that often coexist with CRSwNP.&#xD;
We will use oral Montelukast (montelukast 10 mg, once a day) for 3 monthes</description>
    <arm_group_label>Montelukast Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Oral Prednisolone 40 mg/day for two weeks.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Montelukast Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Furoate</intervention_name>
    <description>fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Montelukast Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - 1- Adult patients (aged 18 years and over)&#xD;
&#xD;
          -  2- Bilateral denovo nasal polyps confirmed by nasal endoscopy and CT scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - 1- CRS patients without nasal polyposis.&#xD;
&#xD;
          -  2- Patient with unilateral nasal polyp.&#xD;
&#xD;
          -  3- Revision cases (history of previous surgical treatment).&#xD;
&#xD;
          -  4- Patient with fungal rhinosinusitis..&#xD;
&#xD;
          -  5- Pregnancy and lactation.&#xD;
&#xD;
          -  6- Malignancies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hossam Aldein Samir Mohamed</last_name>
    <phone>01019858519</phone>
    <email>hosam.20133977@med.au.edu.eg</email>
  </overall_contact>
  <reference>
    <citation>Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012 Mar;50(1):1-12. doi: 10.4193/Rhino12.000.</citation>
    <PMID>22469599</PMID>
  </reference>
  <reference>
    <citation>Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016 Mar 14;9:45-53. doi: 10.2147/JAA.S86251. eCollection 2016. Review.</citation>
    <PMID>27042129</PMID>
  </reference>
  <reference>
    <citation>Johansson L, Akerlund A, Holmberg K, Melén I, Bende M. Prevalence of nasal polyps in adults: the Skövde population-based study. Ann Otol Rhinol Laryngol. 2003 Jul;112(7):625-9.</citation>
    <PMID>12903683</PMID>
  </reference>
  <reference>
    <citation>Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, Wang H, Zhang L, Bachert C. Diversity of T(H) cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016 Nov;138(5):1344-1353. doi: 10.1016/j.jaci.2016.05.041. Epub 2016 Jul 15.</citation>
    <PMID>27544740</PMID>
  </reference>
  <reference>
    <citation>Scadding GK, Durham SR, Mirakian R, Jones NS, Drake-Lee AB, Ryan D, Dixon TA, Huber PA, Nasser SM; British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy. 2008 Feb;38(2):260-75. doi: 10.1111/j.1365-2222.2007.02889.x. Epub 2007 Dec 20.</citation>
    <PMID>18167126</PMID>
  </reference>
  <reference>
    <citation>Joe SA, Thambi R, Huang J. A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2008 Sep;139(3):340-7. doi: 10.1016/j.otohns.2008.05.628. Review.</citation>
    <PMID>18722209</PMID>
  </reference>
  <reference>
    <citation>Rudmik L, Schlosser RJ, Smith TL, Soler ZM. Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis. Laryngoscope. 2012 Jul;122(7):1431-7. doi: 10.1002/lary.23259. Epub 2012 Mar 12. Review.</citation>
    <PMID>22410935</PMID>
  </reference>
  <reference>
    <citation>Fokkens W, Desrosiers M, Harvey R, Hopkins C, Mullol J, Philpott C, Alobid I, Anselmo-Lima WT, Bachert C, Baroody F, Bernal-Sprekelsen M, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Douglas R, Gevaert P, Hafner A, Hellings P, Joos G, Kalogjera L, Kern R, Knill A, Kocks J, Landis BN, Limpens J, Lebeer S, Lourenco O, Matricardi PM, Meco C, O Mahony L, Reitsma S, Ryan D, Schlosser R, Senior B, Smith T, Teeling T, Tomazic PV, Toppila-Salmi S, Wang DY, Wang D, Zhang L, Lund V. EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis. Rhinology. 2019 Jun 1;57(3):162-168. doi: 10.4193/Rhin17.253.</citation>
    <PMID>30810118</PMID>
  </reference>
  <reference>
    <citation>Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003 Jan;111(1 Suppl):S18-34; discussion S34-6. Review.</citation>
    <PMID>12532084</PMID>
  </reference>
  <reference>
    <citation>Cao Y, Wang J, Bunjhoo H, Xie M, Xu Y, Fang H. Comparison of leukotriene receptor antagonists in addition to inhaled corticosteroid and inhaled corticosteroid alone in the treatment of adolescents and adults with bronchial asthma: a meta-analysis. Asian Pac J Allergy Immunol. 2012 Jun;30(2):130-8.</citation>
    <PMID>22830292</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hossam Aldein Samir Abd Elazeem Mohammed</investigator_full_name>
    <investigator_title>Residant</investigator_title>
  </responsible_party>
  <keyword>Montelukast</keyword>
  <keyword>Chronic Rhinosinusitis with Nasal Polyps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

